OCA
IMA

Octagon Capital Advisors’s ImageneBio Inc IMA Stock Holding History

Octagon Capital Advisors’s Portfolio IMA Stock Details IMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-22,917
Closed -$3.47M – 32
2021
Q3 		$3.47M Sell
22,917
-10,416
-31% -$1.51M 0.85% 24
2021
Q2 		$5.62M Hold
33,333
– – 1.16% 22
2021
Q1 		$11.3M Buy
+33,333
New +$11.4M 4.26% 9

Other funds holding IMA

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Octagon Capital Advisors's IMA Position: Q4 2021 in Review

Octagon Capital Advisors sold out of ImageneBio Inc (IMA) in Q4 2021, closing a stake of 22,917 shares — an estimated $3.47M sold.

Octagon Capital Advisors first reported a position in IMA in Q1 2021 and held it in 3 quarters. The position peaked at $11.3M in Q1 2021. 49 funds tracked by Wall St. Rank hold IMA as of Q4 2021.

  • Octagon Capital Advisors reported no remaining ImageneBio Inc position as of Q4 2021 after selling out during the quarter.
  • Octagon Capital Advisors sold 22,917 ImageneBio Inc shares in Q4 2021, an estimated $3.47M.
  • Octagon Capital Advisors first reported a position in ImageneBio Inc in Q1 2021 and held it in 3 quarters.
  • Octagon Capital Advisors's ImageneBio Inc position peaked at $11.3M in Q1 2021.
  • 49 funds tracked by Wall St. Rank held ImageneBio Inc as of Q4 2021.

Based on Octagon Capital Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.